All Pharma News
ZyVersa Reports Full Year 2023 Financial Results and Provides Business Update

ZyVersa Reports Full Year 2023 Financial Results and Provides Business Update
GLOBENEWSWIRE
25 Mar 2024
Share Share
ZyVersa Announces IRB Approval of Phase 2a Trial Protocol to Evaluate VAR 200

ZyVersa Announces IRB Approval of Phase 2a Trial Protocol to Evaluate VAR 200
GLOBENEWSWIRE
18 Mar 2024
Share Share
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimers Disease

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimers Disease
GLOBENEWSWIRE
24 Jan 2024
Share Share
ZyVersa taps George Clinical to run kidney disease trial

ZyVersa taps George Clinical to run kidney disease trial
Joseph Keenan FIERCE BIOTECH
21 Dec 2023
Share Share
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease

ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease
GLOBENEWSWIRE
07 Dec 2023
Share Share
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology
GLOBENEWSWIRE
01 Nov 2023
Share Share
ZyVersa Announces Publication Substantiating VAR 200™s Rationale

ZyVersa Announces Publication Substantiating VAR 200™s Rationale
GLOBENEWSWIRE
11 Oct 2023
Share Share
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100™s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100™s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
GLOBENEWSWIRE
12 Sep 2023
Share Share
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering

ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
GLOBENEWSWIRE
24 Jul 2023
Share Share
ZyVersa Announces Publication in Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18

ZyVersa Announces Publication in Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18
GLOBENEWSWIRE
17 Jul 2023
Share Share